U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H12O6
Molecular Weight 336.295
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DICUMAROL

SMILES

OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC4=C1C=CC=C4

InChI

InChIKey=DOBMPNYZJYQDGZ-UHFFFAOYSA-N
InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2

HIDE SMILES / InChI

Description
Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728

Dicumarol is an coumarin-like compound found in sweet clover. It is used as oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Dicumarol is also used in biochemical experiments as an inhibitor of reductases.

Originator

Curator's Comment: Campbell, H.A. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry, 138, 21–33.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.0 µM [IC50]
10.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
DICUMAROL

Approved Use

For decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.

Launch Date

1944
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20 μg/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
521 μg × h/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.84 h
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.03%
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 59.8+15.3 years
Health Status: unhealthy
Age Group: 59.8+15.3 years
Sex: M+F
Sources:
2100 mg single, oral
Overdose
Dose: 2100 mg
Route: oral
Route: single
Dose: 2100 mg
Sources:
unknown
Health Status: unknown
Sources:
Disc. AE: Distended blood vessels...
AEs leading to
discontinuation/dose reduction:
Distended blood vessels (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Distended blood vessels 1 patient
Disc. AE
2100 mg single, oral
Overdose
Dose: 2100 mg
Route: oral
Route: single
Dose: 2100 mg
Sources:
unknown
Health Status: unknown
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPα leading to its stabilization and protection against radiation-induced myeloproliferative disease.
2012-12-07
Stress-induced NQO1 controls stability of C/EBPα against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer.
2012-10-04
NAD(P)H:quinone oxidoreductase 1 is induced by progesterone in cardiomyocytes.
2012-06
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
2011-10-27
Cross talk between keratinocytes and dendritic cells: impact on the prediction of sensitization.
2011-10
Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity.
2011-08
Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line.
2011-06
Cost-effective interrogation of single nucleotide polymorphisms using the mismatch amplification mutation assay and capillary electrophoresis.
2010-12
Protective effect of sulforaphane against cisplatin-induced mitochondrial alterations and impairment in the activity of NAD(P)H: quinone oxidoreductase 1 and γ glutamyl cysteine ligase: studies in mitochondria isolated from rat kidney and in LLC-PK1 cells.
2010-11-10
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines.
2010-10-06
Mechanisms of the different DNA adduct forming potentials of the urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone.
2010-07-19
Finding new enzymes from bacterial physiology: a successful approach illustrated by the detection of novel oxidases in Marinomonas mediterranea.
2010-03-05
Analysis of couch position tolerance limits to detect mistakes in patient setup.
2009-10-29
Low levels of the air pollutant 1-nitropyrene induce DNA damage, increased levels of reactive oxygen species and endoplasmic reticulum stress in human endothelial cells.
2009-07-28
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells.
2009-07-15
NAD(P)H quinone oxidoreductase 1 is essential for ozone-induced oxidative stress in mice and humans.
2009-07
The catecholaminergic RCSN-3 cell line: a model to study dopamine metabolism.
2008-06-05
Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro.
2008-02-01
Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target.
2007-12
Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells.
2007-11-01
Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells.
2006-12-08
[Proteus penneri].
2006-10
Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
2006-08-01
Molecular cloning of a novel type of rat cytoplasmic 17beta-hydroxysteroid dehydrogenase distinct from the type 5 isozyme.
2006-06
Mechanism of cell cycle regulation by FIP200 in human breast cancer cells.
2005-08-01
Dicoumarol relieves serum withdrawal-induced G0/1 blockade in HL-60 cells through a superoxide-dependent mechanism.
2005-06-01
Enzymatic properties of a member (AKR1C19) of the aldo-keto reductase family.
2005-06
Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols.
2005-04-01
Dicumarol is a potent reversible inhibitor of gap junctional intercellular communication.
2005-02-15
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells.
2005-02
Chromium (VI)-induced cytotoxicity to osteoblast-derived cells.
1999-12
Fulminant hepatic failure associated with dicoumarol therapy.
1998-02
The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells.
1997-10-15
Roles of DT diaphorase in the genotoxicity of nitroaromatic compounds in human and fish cell lines.
1997-10-10
Coumarin-based inhibitors of HIV integrase.
1997-01-17
Inhibition kinetics of camel lens zeta-crystallin: multiple inhibition studies.
1996-08
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
1996-06-21
Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching.
1996-05-10
Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
1995-04
Aspirin-like drugs can protect human T lymphocytes against benzoquinone cytotoxicity: evidence for a NAD(P)H:quinone reductase-dependent mechanism.
1995
Dicoumarol and warfarin.
1991-08
Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells.
1990-12-01
Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma.
1990
Spontaneous anticoagulant-induced hemopericardium with tamponade.
1982
Comparison of graphical and computerized methods for calculating binding parameters for two strongly bound drugs to human serum albumin.
1976-08
Pineal apoplexy associated with anticoagulant therapy. Case report.
1976-08
Management of thrombo-embolism after aortic valve replacement with the Björk-Shiley tilting disc valve. Medicamental prevention with dicumarol in comparison with dipyridamole - acetylsalicylic acid. Surgical treatment of prosthetic thrombosis.
1975
Intraocular hemorrhage and blindness associated with systemic anticoagulation.
1972-06-05
Unusual gastrointestinal reaction to bishydroxycoumarin(Dicumarol).
1968-07
Urinary tract complications of anticoagulation therapy; "pseudotumour" of the kidney.
1968-03
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Dicoumarol inhibits rat liver microsomal vitamin K epoxide reductase with IC50=2 uM and cytosolic DT-diaphorase with IC50=0.05 uM.
Name Type Language
DICOUMAROL
INN   MART.   WHO-DD   WHO-IP  
INN  
Preferred Name English
DICUMAROL
HSDB   MI   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
dicoumarol [INN]
Common Name English
3,3'-METHYLENEBIS(4-HYDROXYCOUMARIN)
Systematic Name English
DICUMAROL [ORANGE BOOK]
Common Name English
DICOUMAROLUM [WHO-IP LATIN]
Common Name English
DICOUMAROL [WHO-IP]
Common Name English
DICOUMAROL [MART.]
Common Name English
DICUMAROL [USAN]
Common Name English
DICUMAROL [HSDB]
Common Name English
NSC-221570
Code English
DICUMAROL [MI]
Common Name English
2H-1-BENZOPYRAN-2-ONE), 3,3'-METHYLENEBIS(4-HYDROXY-
Systematic Name English
NSC-17860
Code English
DICUMAROL [VANDF]
Common Name English
Dicoumarol [WHO-DD]
Common Name English
NSC-41834
Code English
Classification Tree Code System Code
NCI_THESAURUS C45597
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
WHO-VATC QB01AA01
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
NCI_THESAURUS C263
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
WHO-ATC B01AA01
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
Code System Code Type Description
EVMPD
SUB07101MIG
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
DRUG BANK
DB00266
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
NSC
17860
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
HSDB
3223
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
WIKIPEDIA
DICOUMAROL
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
CHEBI
4513
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DICUMAROL
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY Description: A white or creamy white, crystalline powder; odour, characteristic, faint.Solubility: Practically insoluble in water, ethanol (~750 g/l) TS and ether R.Category: Anticoagulant.Storage: Dicoumarol should be kept in a well-closed container, protected from light.Definition: Dicoumarol contains not less than 98.5% and not more than 101.0% of C19H12O6, calculated with reference to the dried substance.
FDA UNII
7QID3E7BG7
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
MESH
D001728
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
NSC
221570
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
PUBCHEM
54676038
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
SMS_ID
100000082921
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
IUPHAR
6808
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
ALANWOOD
dicoumarol
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
INN
2897
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-632-9
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
RXCUI
1598
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL1466
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
NSC
41834
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
NCI_THESAURUS
C310
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
CAS
66-76-2
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
DRUG CENTRAL
867
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY
MERCK INDEX
m4370
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID8021729
Created by admin on Mon Mar 31 17:46:38 GMT 2025 , Edited by admin on Mon Mar 31 17:46:38 GMT 2025
PRIMARY